Results 181 to 190 of about 21,696 (215)

Dupilumab-Induced Vitiligo Managed Effectively With Nemolizumab and Targeted Topical Therapy. [PDF]

Cureus
Colon J, Falabella A.
europepmc   +1 more source

Immediate versus delayed short-course ruxolitinib for acute GVHD prophylaxis after myeloablative allogeneic hematopoietic stem cell transplantation. [PDF]

Front Immunol
Hua H, Wen S, Wang Y, Niu Z, Song Z, Zhou Z, Sun L, Xu Z, Yuan J, Wang Z, Li H, Zhang X, Wang F.   +12 more
europepmc   +1 more source

Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting. [PDF]

Exp Hematol Oncol
Zhang T, Jiang H, Liu D.
europepmc   +1 more source

CPX-351 in combination with ruxolitinib for advanced-phase myeloproliferative neoplasms: results of a phase 1 study. [PDF]

Blood Neoplasia
Handa S, Madanat Y, Pugh K, Dvorak-Kornaus K, Zhao Q, Mims A, Koenig K, Srisuwananukorn A, Cook R, Swords R, Borate U.   +10 more
europepmc   +1 more source

Second corrigendum to Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease. [PDF]

J Clin Invest
Lin Y, Gu Q, Lu S, Pan Z, Yang Z, Li Y, Yang S, Lv Y, Zheng Z, Sun G, Gou F, Xu C, Zhao X, Wang F, Wang C, Yuan S, Xie X, Cao Y, Liu Y, Gu W, Cheng T, Cheng H, Hu X.   +22 more
europepmc   +1 more source

Effect of anemia developed after ruxolitinib initiation on adverse outcomes in patients with myelofibrosis: a nationwide cohort study. [PDF]

Blood Cancer J
Jeon M, Lee Y, Woo J, Kim JH, Shin JY.
europepmc   +1 more source

Management of BK Polyomavirus in a Kidney Transplant Recipient With Primary Myelofibrosis on JAK-2 Inhibition - A Case Report and Literature Review. [PDF]

Can J Kidney Health Dis
Bywater L, Gill J, Nicholl D.
europepmc   +1 more source

CXCL9 drives lung adenocarcinoma progression and immunotherapy response via activation of the CXCR3/JAK1/STAT3 signaling pathway. [PDF]

Transl Oncol
Ju Q, Chen X, Chang N, Zhou Y, Qiu D, Zhang Y, Zhang J.   +6 more
europepmc   +1 more source

Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study. [PDF]

Clin Pharmacol Ther
Tachet J, Meyer SC, Grandoni F, Haefliger E, Nagy-Hulliger M, Halter JP, Passweg JR, Haefliger D, Bardinet C, Decosterd LA, Guidi M, Girardin FR.   +11 more
europepmc   +1 more source